Drugs and Devices Division
EO Decisions and CED Recommendations
The information below is intended only to provide the recommendations and rationale from the Committee to Evaluate Drugs (CED) and the Executive Officer decisions regarding the listing of products on the Formulary, funding of cancer drugs through the New Drug Funding Program, funding through the Exceptional Access Program, or funding through the Special Drugs Program.
For further details on what types of information is provided, please refer to the Transparency of the Drug Review Process.
Do not rely upon any of the information provided on this site for medical diagnosis or treatment. Please consult your primary health care provider about any personal health concerns. This website does not provide any medical diagnosis, symptom assessment, health counseling or medical opinion for individual users. The information contained on this site is intended for information purposes only and does not constitute medical advice for patients. For more detailed information on prescription drugs, please consult a qualified healthcare professional.
| Brand Name | Generic Name | Date Published |
|---|---|---|
| A | ||
| Azilect | rasagiline | August 2008 |
| C | ||
| Cipralex | escitalopram | October 2007 |
| Cymbalta – diabetic peripheral neuropathic pain | duloxetine | April 2009 |
| E | ||
| Elaprase | idursulfase | May 2008 |
| I | ||
| Invega | paliperidone | December 2008 |
| J | ||
| Januvia | sitagliptin | December 2010 |
| L | ||
| Leukotriene Receptor Antagonists (Singulair, Accolate) | leukotriene receptor antagonists (montelukast, zafirlukast) | September 2008 |
| R | ||
| Revatio | sildenafil | May 2008 |
| Rituxan | rituximab | January 2008 |
| T | ||
| Tysabri | natalizumab | June 2008 |
Public Information
